A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA



If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.